Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy
Source abstract
Abstract
Tumor infiltrating lymphocyte therapy (TIL therapy) is one of the effective treatments for solid tumors. However, certain periods or sites of solid tumors are not amenable to surgical resection. Meanwhile, the abundant and dense extracellular matrix (ECM) and regulatory cells (e.g., regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC)) in solid tumors when infused back into the treatment will prevent T cell infiltration and proliferation, thus inhibiting the efficacy of this approach. In this study, a novel cell preparation was successfully developed by integrating microfluidic chip design with carbodiimide chemical modification. This preparation was surface modified with BTN2A2 antibodies and internally contained T cells isolated from the blood of tumor hosts, along with simulated collagen peptide CMP. Specifically, the cell preparation exerted its anti-tumor effects through multiple mechanisms: Firstly, the surface BTN2A2 antibodies effectively inhibited the proliferation of Tregs and MDSCs within the tumor microenvironment; Secondly, leveraging the T cell antigen receptors (TCRs) present in the blood T cells, which were similar to those of tumor-infiltrating lymphocytes, significantly enhanced their targeting and cytotoxic capabilities; Furthermore, the CMP component within the droplets effectively promoted the infiltration of T cells into tumor tissues. In the complex immunosuppressive microenvironment, the synergistic action of these components markedly enhanced the clearance efficacy of the immune system. Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Microfluidic and Bio-sensing Technologies · Innovative Microfluidic and Catalytic Techniques Innovation · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Tumor-infiltrating lymphocyte therapy in advanced melanoma10.1056/NEJMc2300132 ↗
2. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers10.1038/d41573-024-00035-1 ↗
3. Tumor-infiltrating lymphocytes in the immunotherapy era10.1038/s41423-020-00565-9 ↗
4. The landscape of T cell antigens for cancer immunotherapy10.1038/s43018-023-00588-x ↗
5. Challenges and new technologies in adoptive cell therapy10.1186/s13045-023-01492-8 ↗
6. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines10.1038/s41571-020-00460-2 ↗
7. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
8. Advances in the clinical management of uveal melanoma10.1038/s41571-022-00714-1 ↗
9. Engineering interferons and interleukins for cancer immunotherapy10.1016/j.addr.2022.114112 ↗
10. Emerging cellular therapies for cancer10.1146/annurev-immunol-042718-041407 ↗
11. Expanding CAR-T cell immunotherapy horizons through microfluidics10.1039/D3LC00622K ↗
12. Microfluidic chips: emerging technologies for adoptive cell immunotherapy10.3390/mi14040877 ↗
13. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow10.1039/D3LC00311F ↗
14. Personalized gel-droplet monocyte vaccines for cancer immunotherapy10.1039/D1LC00646K ↗
15. Microfluidic-based preparation of artificial antigen-presenting gel droplets for integrated and minimalistic adoptive cell therapy strategies10.1088/1758-5090/ad2fd4 ↗
16. Non-invasive T cells adoptive immunotherapy for solid tumor with gel anti-tumor T-cell injections10.1016/j.cej.2022.135839 ↗
17. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients10.1038/nm.4051 ↗
18. BTN2A2 protein negatively regulates T cells to ameliorate collagen-induced arthritis in mice10.1038/s41598-021-98443-5 ↗
19. Butyrophilins: an important new element of resistance10.5114/ceji.2017.72806 ↗
20. BTN2A2, a new biomarker and therapeutic target for glioma
21. Prediction of disordered regions and their roles in the anti-pathogenic and immunomodulatory functions of butyrophilins10.3390/molecules23020328 ↗
22. Butyrophilin 2a2 (Btn2a2) expression on thymic epithelial cells promotes central T cell tolerance and prevents autoimmune disease10.1016/j.jaut.2023.103071 ↗
23. BTN2A2-Ig protein inhibits the differentiation of pathogenic Th17 cells and attenuates EAE in mice10.1016/j.imlet.2023.06.009 ↗
24. Biopolymer implants enhance the efficacy of adoptive T-cell therapy10.1038/nbt.3104 ↗
25. Direct isolation of circulating extracellular vesicles from blood for vascular risk profiling in type 2 diabetes mellitus10.1039/D1LC00333J ↗
26. Integrated inertial-impedance cytometry for rapid label-free leukocyte isolation and profiling of neutrophil extracellular traps (NETs)10.1039/C9LC00250B ↗
27. Inertial microfluidics for continuous particle separation in spiral microchannels10.1039/b908271a ↗
28. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics10.1038/nprot.2016.003 ↗
29. Multiplexed label-free fractionation of peripheral blood mononuclear cells for identification of monocyte-platelet aggregates10.1021/acs.analchem.8b04415 ↗
30. Droplet microfluidics--a tool for single-cell analysis10.1002/anie.201200460 ↗
31. The Poisson distribution and beyond: methods for microfluidic droplet production and single cell encapsulation10.1039/C5LC00614G ↗
32. Alginate: properties and biomedical applications10.1016/j.progpolymsci.2011.06.003 ↗
33. Nanobodies: chemical functionalization strategies and intracellular applications10.1002/anie.201708459 ↗
34. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
35. Modular design of supramolecular organic frameworks for image‐guided photodynamic therapy
36. Clinical immunotherapy in pancreatic cancer10.1007/s00262-024-03632-6 ↗
37. Current clinical strategies of pancreatic cancer treatment and open molecular questions10.3390/ijms20184543 ↗
38. Overcoming immune evasion in melanoma10.3390/ijms21238984 ↗
39. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma10.1080/14737140.2019.1622417 ↗
40. Biocompatible surfactants for water-in-fluorocarbon emulsions10.1039/b806706f ↗
41. Microfluidic templated multicompartment microgels for 3D encapsulation and pairing of single cells